Advanced search
Publication Cover
Expert Review of Hematology Volume 6, 2013 - Issue 3
Submit an article Journal homepage
296
Views
8
CrossRef citations to date
0
Altmetric
Drug Profile

Iron (III) isomaltoside 1000

Thomas AR Mace Hull York Medical School, Hertford Building, University of Hull, Hull, HU6 7RX, UK. [email protected]; Hull and East Yorkshire NHS Trust, Renal Secretaries, Alderson House, Hull Royal Infirmary, Anlaby Road, Hull, HU3 2JZ, UK; Hull York Medical School, Hertford Building, University of Hull, Hull, HU6 7RX, UK. [email protected]; Hull and East Yorkshire NHS Trust, Renal Secretaries, Alderson House, Hull Royal Infirmary, Anlaby Road, Hull, HU3 2JZ, UK
,
Ahsan Syed Hull and East Yorkshire NHS Trust, Renal Secretaries, Alderson House, Hull Royal Infirmary, Anlaby Road, Hull, HU3 2JZ, UK; Hull and East Yorkshire NHS Trust, Renal Secretaries, Alderson House, Hull Royal Infirmary, Anlaby Road, Hull, HU3 2JZ, UK
&
Sunil Bhandari Hull York Medical School, Hertford Building, University of Hull, Hull, HU6 7RX, UK. [email protected]; Hull and East Yorkshire NHS Trust, Renal Secretaries, Alderson House, Hull Royal Infirmary, Anlaby Road, Hull, HU3 2JZ, UK; Hull York Medical School, Hertford Building, University of Hull, Hull, HU6 7RX, UK. [email protected]; Hull and East Yorkshire NHS Trust, Renal Secretaries, Alderson House, Hull Royal Infirmary, Anlaby Road, Hull, HU3 2JZ, UK
Pages 239-246 | Published online: 10 Jan 2014

References

  • McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993–2005. Public Health Nutr. 12(4), 444–454 (2009).
  • WHO, UNICEF, UNU. Iron Deficiency Anaemia: Assessment, Prevention and Control. A Guide for Programme Managers. World Health Organization, Geneva, Switzerland (2001).
  • Clark SF. Iron deficiency anemia. Nutr. Clin. Pract. 23(2), 128–141 (2008).
  • Bhandari S. Risk factors and metabolic mechanisms in the pathogenesis of uraemic cardiac disease. Front. Biosci. 16, 1364–1387 (2011).
  • de Silva R, Rigby AS, Witte KK et al. Anemia, renal dysfunction, and their interaction in patients with chronic heart failure. Am. J. Cardiol. 98(3), 391–398 (2006).
  • Kidney disease: improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. 2(4), S279–S335 (2012).
  • National Collaborating Centre for Chronic Conditions. In: Anaemia Management in Chronic Kidney Disease: National Clinical Guideline for Management in Adults and Children. Royal College of Physicians, London, UK (2006).
  • Gotloib L, Silverberg D, Fudin R, Shostak A. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J. Nephrol. 19(2), 161–167 (2006).
  • Smrzova J, Balla J, Bárány P. Inflammation and resistance to erythropoiesis-stimulating agents – what do we know and what needs to be clarified? Nephrol. Dial. Transplant. 20(Suppl. 8), viii2–viii7 (2005).
  • Pfeffer MA, Burdmann EA, Chen CY et al.; TREAT Investigators. A trial of darbepoetin alfa in Type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361(21), 2019–2032 (2009).
  • Singh AK, Szczech L, Tang KL et al.; CHOIR Investigators. Correction of anemia with epoetin α in chronic kidney disease. N. Engl. J. Med. 355(20), 2085–2098 (2006).
  • Weiss G, Goodnough LT. Anemia of chronic disease. N. Engl. J. Med. 352(10), 1011–1023 (2005).
  • Chaplin S, Bhandari S. Oral iron: properties and current place in the treatment of anaemia. Prescriber 23, 12–18 (2012).
  • Melamed N, Ben-Haroush A, Kaplan B, Yogev Y. Iron supplementation in pregnancy – does the preparation matter? Arch. Gynecol. Obstet. 276(6), 601–604 (2007).
  • Bhandari S, Owda AK, Kendall RG et al. Red cell ferritin, a marker of iron deficiency in hemodialysis patients. Ren. Fail. 19(6), 771–780 (1997).
  • Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int. Suppl. 69, S61–S66 (1999).
  • Albaramki J, Hodson EM, Craig JC, Webster AC. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst. Rev. 1, CD007857 (2012).
  • Reinso® (ferumoxytol), prescribing information. Takeda Pharmaceuticals, Osaka, Japan (2012).
  • Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J. Am. Soc. Nephrol. 15(Suppl. 2), S93–S98 (2004).
  • Wikström B, Bhandari S, Barany P et al. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease. J. Nephrol. 24(5), 589–596 (2011).
  • Hildebrandt PR, Bruun NE, Nielsen OW et al. Effects of administration of iron isomaltoside 1000 in patients with chronic heart failure: a pilot study. Transfus. Altern. Transfus. Med. 11(4), 131–137 (2010).
  • Ganzoni AM. Intravenous iron-dextran: therapeutic and experimental possibilities. Schweiz. Med. Wochenschr. 100(7), 301–303 (1970).
  • Monofer® (iron isomaltoside 1000), prescribing information. Pharmacosmos, Holbaek, Denmark (2012).
  • Jahn MR, Andreasen HB, Fütterer S et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur. J. Pharm. Biopharm. 78(3), 480–491 (2011).
  • Nordfjeld K, Andreasen H, Thomsen LL. Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease. Drug Des. Devel. Ther. 6, 43–51 (2012).
  • Zager RA, Johnson AC, Hanson SY. Parenteral iron therapy exacerbates experimental sepsis. Kidney Int. 65(6), 2108–2112 (2004).
  • Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. Update on adverse drug events associated with parenteral iron. Nephrol. Dial. Transplant. 21(2), 378–382 (2006).
  • Kalra PA, Bock K, Meldal M. Iron isomaltoside 1000: a new high dose option for parenteral iron therapy. Port. J Nephrol. Hypertens. 26(1), 13–24 (2012).
  • Ljungström KG, Renck H, Hedin H, Richter W, Wiholm BE. Hapten inhibition and dextran anaphylaxis. Anaesthesia 43(9), 729–732 (1988).
  • Kalra PA, Bhandari S, Thomsen LL. One visit iron repletion with iron isomaltoside 1000 (Monofer®) in CKD and CHF patients. Presented at: ASN 43rd Annual Meeting. Denver, CO, USA, 16–21 November 2010.
  • Nath KA, Vercellotti GM, Grande JP et al. Heme protein-induced chronic renal inflammation: suppressive effect of induced heme oxygenase-1. Kidney Int. 59(1), 106–117 (2001).
  • Van Wyck DB. Labile iron: manifestations and clinical implications. J. Am. Soc. Nephrol. 15(Suppl. 2), S107–S111 (2004).
  • Toblli JE, Cao G, Oliveri L, Angerosa M. Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model. Inflamm. Allergy Drug Targets 11(1), 66–78 (2012).
  • Zager RA. Parenteral iron compounds: potent oxidants but mainstays of anemia management in chronic renal disease. Clin. J. Am. Soc. Nephrol. 1(Suppl. 1), S24–S31 (2006).
  • Zager RA, Johnson AC, Hanson SY. Parenteral iron nephrotoxicity: potential mechanisms and consequences. Kidney Int. 66(1), 144–156 (2004).
  • Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int. 65(6), 2279–2289 (2004).
  • Auerbach M, Ballard H, Trout JR et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J. Clin. Oncol. 22(7), 1301–1307 (2004).
  • Bhandari S, Naudeer S. Improving efficiency and value in health care. Intravenous iron management for anaemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choice. J. Eval. Clin. Pract. 14(6), 996–1001 (2008).
  • Ferinject® (ferric carboxymaltose), prescribing information. Vifor Pharmaceuticals, Glattbrugg, Switzerland (2011).
  • Auerbach M, Pappadakis JA, Bahrain H, Auerbach SA, Ballard H, Dahl NV. Safety and efficacy of rapidly administered (1 hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia. Am. J. Hematol. 86(10), 860–862 (2011).
  • Cooke M, Lamplugh A, Naudeer S, Edey M, Bhandari S. Efficacy and tolerability of accelerated-dose low-molecular-weight iron dextran (Cosmofer) in patients with chronic kidney disease. Am. J. Nephrol. 35(1), 69–74 (2012).
  • Venofer® (iron sucrose), prescribing information. Vifor Pharmaceuticals, Glattsbrugg, Switzerland (2011).
  • Bhandari S. Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice. Ther. Clin. Risk Manag. 7, 501–509 (2011).
  • Sasu BJ, Cooke SC, Arvedson TL et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood 115(17), 3616–3625 (2009).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.